NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Incyte Corporation (NASDAQ: INCY)

 
INCY Technical Analysis
3
As on 29th Apr 2025 INCY STOCK Price closed @ 60.43 and we RECOMMEND Buy for LONG-TERM with Stoploss of 59.94 & Buy for SHORT-TERM with Stoploss of 59.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

INCYSTOCK Price

Open 59.39 Change Price %
High 60.72 1 Day 0.91 1.53
Low 58.04 1 Week 2.22 3.81
Close 60.43 1 Month -1.58 -2.55
Volume 2931817 1 Year 7.91 15.06
52 Week High 83.38 | 52 Week Low 51.18
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
WW 0.73 78.05%
PTPI 0.01 -83.33%
GNLN 0.01 0.00%
AGMH 0.10 -23.08%
BON 0.07 16.67%
PLUG 0.96 -5.88%
SOFI 13.27 0.53%
NVDA 109.02 0.27%
DGLY 0.04 33.33%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
KTTAW 0.03 200.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
BCAC 22.71 125.30%
CFFEW 0.11 120.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTPI 0.01 -83.33%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
ADXS 0.03 -70.00%
BPTH 0.21 -66.67%
TFFP 0.06 -62.50%
MILEW 0.06 -53.85%
 
 
INCY
Daily Charts
INCY
Intraday Charts
Whats New @
Bazaartrend
INCY
Free Analysis
 
INCY Important Levels Intraday
RESISTANCE65.59
RESISTANCE63.94
RESISTANCE62.91
RESISTANCE61.89
SUPPORT58.97
SUPPORT57.95
SUPPORT56.92
SUPPORT55.27
 
INCY Forecast April 2025
4th UP Forecast79.18
3rd UP Forecast73.17
2nd UP Forecast69.45
1st UP Forecast65.73
1st DOWN Forecast55.13
2nd DOWN Forecast51.41
3rd DOWN Forecast47.69
4th DOWN Forecast41.68
 
INCY Weekly Forecast
4th UP Forecast66.98
3rd UP Forecast64.88
2nd UP Forecast63.58
1st UP Forecast62.28
1st DOWN Forecast58.58
2nd DOWN Forecast57.28
3rd DOWN Forecast55.98
4th DOWN Forecast53.88
 
INCY Forecast2025
4th UP Forecast125.18
3rd UP Forecast104.41
2nd UP Forecast91.58
1st UP Forecast78.74
1st DOWN Forecast42.12
2nd DOWN Forecast29.28
3rd DOWN Forecast16.45
4th DOWN Forecast-4.32
 
 
INCY Other Details
Segment EQ
Market Capital 14517693440.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
INCY Address
INCY
 
INCY Latest News
 
Your Comments and Response on Incyte Corporation
 
INCY Business Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service